|Issue Date||16/06 - 20/06|
|Issue Size||₹1741.16 Cr|
|Market Lot||24 Shares|
|Shares on Offer||28,875,000|
|Subject to Sauda||N/A|
Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology. Their focus has been on developing, manufacturing and marketing products which are linked to lifestyle related disorders that are chronic in nature and are treated by superspecialist and specialist doctors.
They have a team of over 2287 employees across India as on September 30, 2016. Their specialty field force consists of 1300+ medical representatives and 612 field managers. Their teams at the manufacturing facility and corporate office together comprise of 365 employees.
Eris features amongst the Top 30 companies in the Indian Branded Formulations Market.
Their core commitment is towards improving health care outcomes and adding value for all their stakeholders including patients, doctors, regulators, employees and business partners.
They aim to become most admired company by doctors, patients, employees and all channel partners.
They are committed to patients and doctors as users of their products; they will strive to do their best at every step of the chain by providing best of the products and services.
They will make ongoing efforts to innovate their products to bring the best clinical practices in health care industry to their customers.
They will conduct ourselves with high integrity to ensure respect of their colleagues is maintained and their excellence is recognized; they aspire to provide best of compensation and career opportunities to their colleagues.
Incorporated in 2007, Eris Lifescience Ltd is Ahmedabad, Gujrat based pharmaceutical company engaged in research, development, manufacturing and selling of select therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market.
Eris product portfolio is primarily focused on therapeutic areas which require the intervention of super specialist and specialist doctors such as Diabetologists, Endocrinologists Cardiologists, and Gastroenterologists.
Eris products in the chronic category cater primarily to the therapeutic areas including cardiovascular, anti-diabetics and neurology, chronic respiratory and chronic pain (analgesics).
In acute category, the product portfolio includes vitamins, gastroenterology, anti-infectives, gynaecology, cute respiratory, acute pain (analgesics), hepatoprotectives, hormones, hematology, dermatology, anti-obesity products and products for injury healing.
Eris Lifescience own and operate a manufacturing facility in Guwahati, Assam. They also outsource the manufacturing of certain of its products to 20 manufacturers. Eris strong sales team comprised of 1,310 marketing representatives.
|Total Assets (In ₹ Millions)||3,973.59||3,572.85||2,705.99||1,718.05||1,019.67|
|Total Revenue (In ₹ Millions)||5,970.21||5,455.58||5,088.22||3,930.64||2,739.40|
|Profit After Tax (PAT) (In ₹ Millions)||1,348.58||892.59||709.12||584.40||370.63|
|Date & Time||QIB||NII||RII||Total|
|Day 1 - June 16,2017||0.07||0.02||0.41||0.12|
|Day 2 - June 19,2017||0.82||0.03||1.68||0.75|
|Day 3 - June 20,2017||4.68||0.45||3.51||3.29|
Please click the link below to check the IPO allotment status.IPO Allotment Status
Eris Lifesciences Limited IPO IPO will open on 16/06 and close on 20/06.
Eris Lifesciences Limited IPO IPO will list on 29/06.
The offer price of Eris Lifesciences Limited IPO IPO is ₹600-603.
The lot size of Eris Lifesciences Limited IPO IPO is 24.
The Grey Market Premium (GMP) price of Eris Lifesciences Limited IPO IPO is ₹73-76.
The Kostak price of Eris Lifesciences Limited IPO IPO is ₹300.
The Subject to Sauda price for Eris Lifesciences Limited IPO IPO is Not Available at the moment.
Please Leave Your Message